Metastatic prostate cancer may have its own biomarker, research finds

Prostate cancer can grow slowly and pose little threat to patients, or it can metastasize quickly, causing severe pain and death. But as of now, it’s nearly impossible to determine which type of cancer a patient has during the early stages. Now, University at Buffalo researchers and scientists from Moscow State University are collaborating to determine how a biomarker for […]

Continue reading »

T cell biomarker predicts which CLL patients will respond to CAR T cell therapy

Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are before the therapy is administered. While 80 percent of patients with advanced acute lymphoblastic leukemia (ALL) treated with the CAR T […]

Continue reading »